NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.

The main questions it aims to answer are:

1. Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy?
2. Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?

Inclusion Criteria:

• Clincial dianogsis of acute lymphoblastic leukemia (B-cell type) by morphology, immunology, cytogenetics, and molecular biology (MICM).
• Age ≥1 year and <18 years.
• Informed consent signed, with the parents or guardians agreeing to a unified treatment protocol.

Exclusion Criteria:

• Age <1 year or ≥18 years.
• Immunophenotyping suggests mature B-cell leukemia, mixed-lineage leukemia, or T-cell acute lymphoblastic leukemia.
• Secondary leukemia or second tumor, CML blast phase ALL.
• Other tumors or immunodeficiency diseases present.